View Author
patient leukemia myeloid leukemia group myeloid study treatment blood survival expression response cytogenetic cytarabine therapy trial result cycle remission chemotherapy analysis imatinib table marrow number outcome induction disease blast phase university j clin oncol month count cancer syndrome prognostic abnormality evi 1 factor adult diagnosis level myelodysplastic donor relapse center erasmus mc cytogenetic response sample combination 3-itd death myelodysplastic syndromes netherland square meter event-free survival erasmu value mutation effect flt 3-itd ratio high-dose event-free hospital signi daunorubicin marker consolidation figure transplantation toxicity resistance myelodysplastic syndrome erasmus university karyotype evi 1 expression randomized wbc count cd 34ϩcd cells
10 Most Recent Publications
|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
(Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H. |
2013-04-10
|
|
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: Relevance of mutated NPM1 and FLT3-ITD
(Article)
Jonge, H.J.M. de Valk, P.J.M. Bont, E.S.J.M. de Schuringa, J.J. Ossenkoppele, G.J. Vellenga, E. Huls, G. |
2011-09-01
|
|
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
(Article)
Rijneveld, A.W. Holt, B. van der Wijermans, P. Wittebol, S. Spoelstra, F.M. Dekker, A.W. Ossenkoppele, G.J. Willemze, R. Cornelissen, J.J. Daenen, S.M.G.J. Biemond, B.J. de Weerdt, O. Muus, P. Maertens, J. Mattijssen, V. Demuynck, H. Legdeur, M.C.J.C. |
2011-06-07
|
|
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: Implications for immunotherapy
(Article)
Aggarwal, S. Loosdrecht, A.A. van de Alhan, C. Ossenkoppele, G.J. Westers, T.M. Bontkes, H.J. |
2011-06-01
|
|
Cytarabine dose for acute myeloid leukemia
(Article)
Löwenberg, B. Pabst, T. Greef, G.E. de Verdonck, L.F. Schaafsma, M.R. Gregor, M. Theobald, M. Schanz, U. Maertens, J. Ossenkoppele, G.J. Vellenga, E. Putten, W. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Biemond, B.J. Gratwohl, A. |
2011-03-17
|
|
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib
(Article)
Deenik, W. Holt, B. van der Janssen, J.J.W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Heiden, I.P. van der Sonneveld, P. Schaik, R.H.N. van Cornelissen, J.J. |
2010-12-23
|
|
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
(Article)
Löwenberg, B. Morgan, G. Bone, E. Flores, N. Richardson, A.F. Hooftman, L. Jenkins, C. Davies, F. Ossenkoppele, G.J. Burnett, A.K. Zachée, P. Dührsen, U. Dierickx, D. Müller-Tidow, C. Sonneveld, P. Krug, U. |
2010-10-01
|
|
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome
(Article)
Sanz, M.A. Montesinos, P. Rivas, C. Krsnik, I. Bergua, J.M. González, J.D. Díaz-Mediavilla, J. Rojas, R. Manso, F. Ossenkoppele, G.J. Löwenberg, B. Rayón, C. Holowiecka, A. Serna, J. De La Milone, G. Lisa, E. de Brunet, S. Rubio, V. Ribera, J.M. |
2010-06-24
|
|
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Janssen, J.J.W.M. Sonneveld, P. Marwijk Kooy, M. van Wittebol, S. Willemze, R. Wijermans, P.W. Beverloo, H.B. Löwenberg, B. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Holt, B. van der Verhoef, G.E.G. Smit, W.M. Kersten, M.J. Daenen, S.M.G.J. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. |
2010-06-01
|
|
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells
(Article)
Janssen, J.J.W.M. Denkers, F. Valk, P.J.M. Cornelissen, J.J. Schuurhuis, G.J. Ossenkoppele, G.J. |
2010-06-01
|
